Skip Navigation


JAC Advance Access originally published online on February 12, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
53/3/526    most recent
dkh106v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Favel, A.
Right arrow Articles by Regli, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Favel, A.
Right arrow Articles by Regli, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2004) 53, 526-529
© 2004 The British Society for Antimicrobial Chemotherapy

Susceptibility of clinical isolates of Candida lusitaniae to five systemic antifungal agents

Anne Favel1,*, Annie Michel-Nguyen2, Annick Datry3, Svetlana Challier4, Florence Leclerc5, Christiane Chastin5, Karim Fallague1 and Patrick Regli1

1 Laboratoire de Botanique, Cryptogamie et Biologie cellulaire, Faculté de Pharmacie, 13385 Marseille; 2 Laboratoire Central Hôpital Saint Joseph et Laboratoire de Microbiologie CHU Nord, 13000 Marseille; 3 Service de Parasitologie-Mycologie, Groupe Hospitalier Pitié-Salpêtrière, 75651 Paris; 4 Laboratoire de Microbiologie, Hôpital Necker, 75015 Paris; 5 Laboratoire des Sciences végétales, Faculté des Sciences pharmaceutiques et biologiques, 75006 Paris, France

Received 22 September 2003; returned 22 October 2003; revised 21 November 2003; accepted 10 December 2003

Objectives: The aim of the present study was to expand the MIC database for Candida lusitaniae in order to further determine its antifungal susceptibility pattern.

Methods: The activities of amphotericin B, fluconazole, itraconazole, voriconazole and flucytosine were determined in vitro against 80 clinical isolates of C. lusitaniae. A set of 59 clinical isolates of Candida albicans and of 51 isolates of Candida glabrata was included to compare the susceptibilities to amphotericin B. The MICs were determined by Etest with RPMI 1640 agar, and with both this medium and antibiotic medium 3 (AM3) agar for testing of amphotericin B.

Results: All isolates were highly susceptible to fluconazole. The susceptibility to itraconazole was good; only 4% of isolates had dose-dependent susceptibility (MICs 0.25–0.5 mg/L). Voriconazole was very active in vitro (100% of isolates were inhibited at <=0.094 mg/L). Flucytosine MICs ranged widely (0.004–>32 mg/L). The set included 19% of flucytosine-resistant isolates. For amphotericin B, 100% of isolates were inhibited at <=0.75 mg/L (MIC50 0.047 mg/L; MIC90 0.19 mg/L) and at <=4 mg/L (MIC50 0.25 mg/L; MIC90 0.75 mg/L) on RPMI and on AM3, respectively. A single isolate was categorized as resistant to amphotericin B (MIC 0.75 and 4 mg/L on RPMI and on AM3, respectively). Amphotericin B thus appeared very active in vitro against C. lusitaniae. Whatever the test medium, the level of susceptibility of C. lusitaniae to amphotericin B did not differ much from those of C. albicans and C. glabrata.

Conclusion: C. lusitaniae appears to be susceptible to amphotericin B, azole antifungal agents, and, to a lesser extent, flucytosine.

Keywords: C. lusitaniae, antifungals, susceptibility patterns, Etest

* Correspondence address. Laboratoire de Botanique, Cryptogamie et Biologie cellulaire, Faculté de Pharmacie, 27 Boulevard J. Moulin, 13385 Marseille Cedex 5, France. Tel: +33-4-91-83-56-37; Fax: +33-4-91-80-26-12; E-mail: anne.favel{at}pharmacie.univ-mrs.fr


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Microbiol. Rev.Home page
M. A. Pfaller and D. J. Diekema
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Clin. Microbiol. Rev., January 1, 2007; 20(1): 133 - 163.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
P.-R. Hsueh, Y.-J. Lau, Y.-C. Chuang, J.-H. Wan, W.-K. Huang, J.-M. Shyr, J.-J. Yan, K.-W. Yu, J.-J. Wu, W.-C. Ko, et al.
Antifungal Susceptibilities of Clinical Isolates of Candida Species, Cryptococcus neoformans, and Aspergillus Species from Taiwan: Surveillance of Multicenter Antimicrobial Resistance in Taiwan Program Data from 2003
Antimicrob. Agents Chemother., February 1, 2005; 49(2): 512 - 517.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. P. Pai and A. L. Jones
Altered Susceptibility of Candida glabrata Bloodstream Isolates to Triazoles at Clinically Relevant pH Values: Comparison of the NCCLS M27-A2, Sensititre YeastOne, and Etest Methods
Antimicrob. Agents Chemother., November 1, 2004; 48(11): 4441 - 4443.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
G. Di Bonaventura, I. Spedicato, C. Picciani, D. D'Antonio, and R. Piccolomini
In Vitro Pharmacodynamic Characteristics of Amphotericin B, Caspofungin, Fluconazole, and Voriconazole against Bloodstream Isolates of Infrequent Candida Species from Patients with Hematologic Malignancies
Antimicrob. Agents Chemother., November 1, 2004; 48(11): 4453 - 4456.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.